Kabi, Mylan and Neptune Thwarted In US Pemetrexed Proceedings

A US vitamin-regimen patent protecting Lilly’s Alimta pemetrexed brand until 2022 is valid, the US Court of Appeals has ruled.

StopSign
A US Court of Appeals ruling has halted potential generics of Lilly's Alimta pemetrexed brand until 2022 • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin